Probucol does not inhibit myeloperoxidase-dependent low-density lipoprotein oxidation as a potent protective effect in atherosclerosis

J Cardiovasc Pharmacol. 2007 Sep;50(3):350-1. doi: 10.1097/FJC.0b013e31809501dc.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anticholesteremic Agents / administration & dosage
  • Anticholesteremic Agents / pharmacology*
  • Atherosclerosis / physiopathology
  • Atherosclerosis / prevention & control*
  • Chlorides / metabolism
  • Enzyme-Linked Immunosorbent Assay / methods
  • Humans
  • Hydrogen Peroxide / metabolism
  • Lipoproteins, LDL / drug effects
  • Lipoproteins, LDL / metabolism*
  • Oxidation-Reduction / drug effects
  • Peroxidase / drug effects
  • Peroxidase / metabolism
  • Probucol / administration & dosage
  • Probucol / pharmacology*
  • Taurine / metabolism

Substances

  • Anticholesteremic Agents
  • Chlorides
  • Lipoproteins, LDL
  • Taurine
  • Hydrogen Peroxide
  • Peroxidase
  • Probucol